Pharmacovigilance Industry Growth, Development and Demand Forecast to 2030

The total value of the pharmacovigilance industry was $6,724.2 million in 2021, and it will grow with a CAGR of 9.5% in the coming years, to further increase to $15,259.8 million by the year 2030. This industrial growth is majorly credited to the increasing occurrence of toxicity and ADRs, surging apprehensions concerning high patient obedience to drug use and drug safety. Moreover, government and non-government administrations are progressively concentrating on drug safety and effectiveness.

Approximately 0.2–24% of the cases of hospitalization are because of ADRs out of which 3.7% of people succumb to deadly ADRs. The principal reasons include a number of prescribed drugs, an increased number of new drugs, an inadequate PV system for ADRs monitoring, and the absence of consciousness and acquaintance with ADRs. In India, the ADR reporting rate is less than 1% while globally it is 5% because of a lack of cognizance about PV and ADR monitoring amongst patients and healthcare providers. 

Oncology had the largest share, of about 27% in the pharmacovigilance market, in the year 2021. Nursing the safety of cancer drugs is enormously significant, because of their side effects. In oncology, these prevent, detect, and management of drug-induced adverse effects, in addition to the evasion of needless medical prescription orders.  There should be awareness among patients regarding the side effects of traditional systemic anti-cancer medicines and innovative targeted therapy.

The process of contract outsourcing allocates the implementation of drug safety functions and procedures to an intermediary. Numerous businesses outsource with the intention of saving on the high initial funding and fixed costs, improving flexibility of resources, and securing further capacity. For small and medium- trades, outsourcing is a lucrative choice. Pharmacovigilance subcontracting is done by advisors, contractors, professional consultancies, service providers, and CROs.

At the global level, North America was the region to generate the highest value in the pharmacovigilance market in 2021 as a result of the existence of advanced healthcare infrastructure, high healthcare outlay, and a growing amount of innovative drug research studies. On the other hand, APAC is expected will have the fastest growth, in excess of 10.6%, in the coming years, largely because of the improving infrastructure of healthcare, growing drug research, and increasing occurrence of enduring pain.

As stated by Congressional Budget Office report, only about 12% of the medications undergoing clinical trials are ultimately permitted for use by the FDA. Also, the normal R&D spending per new drug ranges somewhere between below $1 billion and in excess of $2 billion. These contain the costs of laboratory research as well as clinical trials for effective new drugs, along with the spending on drugs that do not go beyond the stage of laboratory development, come in clinical trials, but miss the mark or are withdrawn by the manufacturer for profit, or are not given approval by the FDA.

With the increase in cases of the side-effect of drugs, and the awareness of the people about drug safety is propelling the demand for pharmacovigilance, all over the world.

Report this Page